Related Experiment Video

Updated: Sep 27, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians

E A Monaco1, M L Vallano

  • 1Department of Pharmacology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

Current Medicinal Chemistry
|February 7, 2003
PubMed

Insights

Cyclin-dependent kinase inhibitors (CDKIs) show promise in treating cancer by halting tumor growth. Emerging research suggests CDKIs also offer neuroprotection, potentially treating neurodegenerative diseases like Alzheimer's disease.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Neuroscience

Background:

  • Small molecule kinase inhibitors targeting cyclin-dependent kinases (CDKs) are crucial cancer therapeutics.
  • CDKs regulate vital cellular processes including cell cycle control and neuronal development.
  • Aberrant CDK activity is implicated in tumorigenesis and neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and stroke.

Purpose of the Study:

  • To explore the therapeutic potential of cyclin-dependent kinase inhibitors (CDKIs).
  • To investigate the role of CDKIs in both oncology and neurodegenerative disease treatment.
  • To highlight the neuroprotective capabilities of CDKIs in preclinical research.

Main Methods:

  • Review of existing literature on CDKIs in cancer and neurodegenerative disease research.
  • Analysis of the mechanisms by which CDK dysregulation contributes to disease pathogenesis.
  • Examination of preclinical data supporting the neuroprotective effects of CDKIs.

Main Results:

  • CDKIs effectively inhibit tumor growth by targeting aberrant CDK activity.
  • Dysregulated CDK activity, particularly of cell cycle CDKs and CDK5, is linked to neuronal apoptosis and dysfunction.
  • CDKIs demonstrate significant neuroprotective potential in laboratory settings.

Conclusions:

  • CDKIs represent a promising therapeutic strategy for various cancers.
  • The neuroprotective properties of CDKIs suggest potential applications in treating neurodegenerative disorders.
  • Further clinical research may establish CDKIs as valuable agents in neurology.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...